Related Experiment Video
Updated: Jul 31, 2025
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas
Hao-Wen Sim1,2,3,4, Selena Lorrey5,6, Mustafa Khasraw7,8,9
1NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, 2050, Australia.
Purpose Of Review:
The management of isocitrate dehydrogenase (IDH)-wildtype glioblastomas is an area of unmet need. Despite multimodal therapy incorporating maximal safe resection, radiotherapy, and temozolomide, clinical outcomes remain poor. At disease progression or relapse, available systemic agents such as temozolomide, lomustine, and bevacizumab have limited efficacy. We review the recent advances in the treatment of IDH-wildtype glioblastomas.
Recent Findings:
A broad repertoire of systemic agents is in the early stages of development, encompassing the areas of precision medicine, immunotherapy, and repurposed medications. The use of medical devices may present opportunities to bypass the blood-brain barrier. Novel clinical trial designs aim to efficiently test treatment options to advance the field. There are a number of emerging treatment options for IDH-wildtype glioblastomas which are undergoing evaluation in clinical trials. Advances in our scientific understanding of IDH-wildtype glioblastomas offer hope and the prospect of incremental improvements in clinical outcomes.
Insights
Treatment options for isocitrate dehydrogenase (IDH)-wildtype glioblastomas are limited. Emerging therapies, including precision medicine and immunotherapy, show promise for improving outcomes in clinical trials.
Area of Science:
- Neuro-oncology
- Translational cancer research
- Clinical trial design
Background:
- Isocitrate dehydrogenase (IDH)-wildtype glioblastomas present a significant unmet need in cancer management.
- Current multimodal therapies (surgery, radiotherapy, temozolomide) yield poor clinical outcomes.
- Existing systemic agents demonstrate limited efficacy at disease progression or relapse.
Purpose of the Study:
- To review recent advances in the treatment of IDH-wildtype glioblastomas.
- To highlight emerging therapeutic strategies and their potential impact.
Main Methods:
- Review of current literature and ongoing clinical trials.
- Analysis of novel systemic agents and treatment modalities.
- Evaluation of advances in scientific understanding of IDH-wildtype glioblastomas.
Main Results:
- A diverse range of systemic agents are under development, including precision medicine, immunotherapy, and repurposed drugs.
- Medical devices offer potential strategies to overcome the blood-brain barrier.
- Novel clinical trial designs are being employed to expedite the evaluation of new treatments.
Conclusions:
- Emerging treatment options for IDH-wildtype glioblastomas are under active investigation in clinical trials.
- Advances in understanding IDH-wildtype glioblastomas provide hope for incremental improvements in patient outcomes.
